Waturu Holding A/S
Company announcement nr. 54
Fredericia, January 26th 2021
Waturu Holding A/S downgrades expectations
Management is lowering the current revenue expectations for 2023, from 140-150 MDKK to a new lower level of 70-80 MDKK with EBITDA in the level 30-35 MDKK.
The downgrade is based on the company's current situation, where negative articles have been written about the company over a longer period of time, which makes it harder to sell the company's products.
About Waturu Holding A/S
Waturu Holding A/S is a Greentech company, which develops innovative water technology for heating or treating water, with the focus on ensuring bacteria-free water and reducing water and energy consumption for heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a major shareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S.
Further information:
CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
Certified Adviser
Tofte & Company ApS
Christian IX Gade 7, 3rd,
1111 København
Phone.: +45 71961030
Contact: Sasja Dalgaard, mobile: +45 26100877, e-mail: sd@toftecompany.com
Website: toftecompany.com
Nasdaq First North Growth Market
Important links:
Websites:
www.waturu.com
Financial reports:
www.waturu.com/documents Further press related news:
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
VoltaGrid LLC20.10.2025 23:15:00 CEST | Press release
VoltaGrid and Halliburton Announce Strategic Collaboration to Deliver Distributed Power Solutions for the Global Data Center Industry
Teva Pharmaceutical Industries Ltd20.10.2025 22:30:00 CEST | Press release
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Vicor Corporation20.10.2025 21:50:00 CEST | Press release
Vicor steps up its IP licensing practice
Biotalys NV20.10.2025 18:00:00 CEST | Press release
Regulated information
Syensqo SA20.10.2025 17:45:00 CEST | Press release
Syensqo - Acquisition of own shares
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom